An interventional study of Part 2 ABR2 At least twice a day for 28 days and Part 1: ABR2 single dose in one eye in Dry Eye Syndrome (DES), sponsored by Pleryon Therapeutics (Hangzhou) Limited. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Pleryon Therapeutics (Hangzhou) Limited · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Dry Eye Syndromes with a site in Canada — 5 open to participants now, 5 under way, 1 of them phase 3. Dry Eye Syndromes · Canada.
Among the 45 studies in Dry Eye Syndromes with a site in Canada, this one is the 23rd largest by planned enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2026, is one of 21 with no phase, and was the 45th registered.
1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →5 of the 45 studies in Dry Eye Syndromes with a site in Canada are open now. Recruiting first, the newest first:
Université de Sherbrooke · Sites in Canada
Ages 18+
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 18+ · Healthy volunteers
Reinhold Vieth · Sites in Canada
Ages 18+ · Healthy volunteers
Uptown Eye Specialists · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 60 across 1,132 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 48 across the 37 interventional studies, 55 across the 8 observational. Of the 37 that completed or were terminated, 18 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 45 have an industry lead sponsor. The 10 most frequent:
Pleryon Therapeutics (Hangzhou) Limited is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Pleryon Therapeutics (Hangzhou) Limited has 1 study filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
1 of the studies in Dry Eye Syndromes with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07593404Pleryon Therapeutics (Hangzhou) LimitedEvaluation of a Novel Ocular Lubricating Eye Drop | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 45 studies in Dry Eye Syndromes with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this 2-part study is to assess the safety and tolerability of the new ocular lubricating drop ABR2 during short-term use in subjects for the temporary relief of ocular discomfort due to dryness of the eye.
In Part 1, participant will receive 1 drop of ABR2 in one eye and through assessments over a 1-hour period.
In Part 2, participant will use 1 drop of ABR2 at least two times a day for 28-day period (may use up to 4 times a day as needed) This is a single arm, open label study with no placebo or comparative arm.
Part 1 has a total of 2 scheduled visits, including Screening and Treatment visit. Participants will attend Part 1 for a total of 3.0 hours.
Part 2 has a total of 6 scheduled visits, including the Screening, baseline \& dispense visit, day 3, 1-week, 2-week, and 4-week Follow Up. Participants will attend Part 2 for a total of 6.5 hours.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Part 1 Participants
Drug: Part 1: ABR2 single dose in one eye
Part 2 Participants
Drug: Part 2 ABR2 At least twice a day for 28 days
Use ABR2 at least BID, up to QID for 28 days
Receive a single dose in one eye only
Number of Adverse Events
Number of adverse events associated with the use of ocular eye drop. Example of adverse events may include, severe conjunctival and palpebral hyperemia, hypersensitivity, allergic reaction, eyelid edema, and photophobia.
Time frame: At the end of Part 1: 60 minutes after single drop monocular instillation and At the end of Part 2 (after 28 days of bilateral use)
Subjective Ratings of Ocular Comfort, Stinging/Burning Sensation and Vision
Participants will be asked to provide subjective ratings of ocular comfort, stinging/burning sensation and vision based on 0-100 rating scale.
Time frame: Part 1: Immediately after drop instillation, 10 minutes, 30 minutes and 60 minutes post drop instillation. Part 2: Upon waking and at the end of day weekly for 4 weeks (Home Questionnaire)
Signs of ocular dryness - Non-invasive tear film break up time (NITBUT)
Non-invasive tear film break up time (NITBUT) will be performed to examine signs of ocular dryness.
Time frame: Part 1: Baseline and 60 minutes after a drop of ABR2 application. Part 2: Baseline, 2 week, and 4 week after ABR2 use
High Contrast High Luminance (HCHI) LogMAR Visual Acuity
Monocular and binocular HCHI VA
Time frame: Part 1: Baseline, immediate, 5 minutes, 10 minutes, 30 minutes and 60 minutes after drop application Part 2: Baseline, day 3, 1-week, 2-week and 4-week follow up
Plan to share: No — Small sample size re-identification risk and limited infrastructure for external data access.
Started May 2026 (actual). Primary completion is estimated for Nov 2026, 6 months after the start.
Of 115 industry-sponsored interventional studies with no phase under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's planned 6 months is below that.
Counting every sponsor, half of 315 studies reached it within 10 months; a quarter within 4 and three quarters within 18.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Jan 2027 → Nov 2026 and completion May 2027 → Feb 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pleryon Therapeutics (Hangzhou) Limited